Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Robin Kate Kelley et al.|NEJM Evidence|2022Cited by 1.4k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Rana Ezzeddine et al.|Journal of Clinical Oncology|2013Cited by 775
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyHideki Ueno, Masao Tanaka, Tatsuya Ioka et al.|Journal of Clinical Oncology|2013Cited by 632
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Anthony B. El-Khoueiry, Ignacio Melero et al.|Journal of Hepatology|2020Cited by 421
Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of ageJin‐Tung Liang, S M Wang, Ming‐Shiang Wu et al.|British journal of surgery|2003Cited by 194